PE Fund Investments
PE firm Advent to acquire 74% stake in TTK's human pharma in Rs.805-Cr spinout
Chennai-based, publicly listed TTK Healthcare is to spin out the company's “human pharma business†to BSV Pharma Pvt Ltd (an affiliate of PE firm Advent International). The total value of the transaction is INR 805 crore, of which 74% will be received by TTK in cash and the balance as equity. The FY21 revenue of TTK's human pharma division, which manufactures medicines for respiratory, infertility, orthopaedic, cardiology and other ailments, was around INR 160 crore (25% of the total turnover of the company).
Want to receive such news items in your inbox? Click Here to sign up for a trial.
